Several dozen LexisNexis employees helped raise nearly $1200, including matching corporate funds, for a Canadian group whose mission is to bring disparate groups together via exposure to the arts. The...
Review this exciting guide to some of the recent content additions to Practical Guidance, designed to help you find the tools and insights you need to work more efficiently and effectively. Practical Guidance...
The following article is a summary of the full checklist , available to Practical Guidance subscribers by following this link . Not yet a Practical Guidance subscriber? Sign up for a free trial here. ...
The following article is a summary of the full practice note , available to Practical Guidance subscribers by following this link . Not yet a Practical Guidance subscriber? Sign up for a free trial here...
The following is a summary of an article by Tom Spiggle, The Spiggle Law Firm Summary of AI in Employment and Regulatory Frameworks Recent years have witnessed a significant transformation in how...
Copyright © 2025 LexisNexis and/or its Licensors.
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
By: Matthew D. Jenkins, Hunton Andrews Kurth LLP
This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response to the COVID-19 pandemic: (1) Medicare’s Advance Payment Program, (2) the Provider Relief Fund, and (3) the Paycheck Protection Program.
When you advise a healthcare company that receives federal funds about its compliance obligations, a basic understanding of the FCA is essential.
The FCA imposes civil penalties on persons who knowingly or with reckless disregard: CLICK HERE TO READ THE FULL ARTICLE IF YOU ARE A PRACTICAL GUIDANCE SUBSCRIBER